GIP and GLP-1 receptor co-agonist
Tirzepatide subcutaneous once weekly, maximum tolerated dose: 10 or 15 mg
TIRZ_SC_MTD_QW
For example SURMOUNT-5. Sensitivity analysis assigns the arm to 15 mg. A different permitted dose set is a different node.
Related
- All doses pooled: Tirzepatide injection
- Tirzepatide 1 mg subcutaneous once weekly
- Tirzepatide 5 mg subcutaneous once weekly
- Tirzepatide 10 mg subcutaneous once weekly
- Tirzepatide 15 mg subcutaneous once weekly
- Tirzepatide maximum tolerated dose injection once weekly
- Tirzepatide 12 mg injection once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -9.01 (-19.87 to 2.82) | 0.91 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -23.57 (-29.15 to -12.76) | 0.93 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -20.61 (-25.15 to -15.27) | 0.99 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 3.93 (-4.38 to 12.06) | 0.78 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.20 (0.49 to 2.96) | 0.49 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 5.13 (2.10 to 13.78) | 0.24 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.28 (2.11 to 5.14) | 0.55 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 11.19 (4.42 to 32.26) | 0.18 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.66 (1.96 to 6.93) | 0.22 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.40 (1.53 to 7.45) | 0.28 |
Trials
- SURMOUNT-5A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities2023 · 751 randomized · 72 weeks
- SURMOUNT-3Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)2021 · 579 randomized · 72 weeks